drugset
drugset / Trial / NCT04658004

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT04658004 ↗

Phase 0 Not yet recruiting 36 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.

Timeline

Start
2021-01-15
Primary completion
2024-01-15
Completion
2027-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject NKG2D CAR T-cells Cell therapy — Intravenous

Indications

acute myeloid leukemia